ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
|
||
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of Each Class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Large accelerated filer
|
☐ |
Accelerated filer
|
☐ | |
|
☒ |
Smaller reporting company
|
||
Emerging growth company
|
PAGE
|
||
NO.
|
||
PART I
|
||
3
|
||
35
|
||
78 |
||
78
|
||
79
|
||
79
|
||
79
|
||
PART II
|
||
79 | ||
83
|
||
83
|
||
98
|
||
100
|
||
131
|
||
131
|
||
131
|
||
131
|
||
PART III
|
||
132
|
||
132
|
||
132
|
||
132
|
||
132
|
||
Part IV
|
||
133
|
||
133
|
||
134
|
• |
Growth or EBITDA positive entities
|
• |
Companies that require capital but do not want to dilute their equity
|
• |
Companies that are showing strong cash flow performance with low leverage profiles
|
• |
Transactions that tend to be attractively priced and have better than normal covenants and amortization due to complexity of the industry
|
• |
Low debt to enterprise value
|
• |
Industry leaders and disruptive companies experiencing strong growth
|
• |
Companies that have raised significant equity capital validating market value
|
• |
Industry focus typically includes software, hardware, e-commerce, direct to consumer and other fast-growing companies
|
• |
Liquidity covenants that ensure such company has adequate cash runway
|
• |
Low debt to enterprise value
|
• |
Profitable or demonstrated path to near term profitability
|
• |
Companies that are showing strong cash flow performance with low leverage profiles, but the industries carry regulatory, reputational or other risks
|
• |
Companies with attractive assets, including, but not limited to, accounts receivable, equipment or real estate
|
• |
Transactions that tend to be attractively priced and have better than normal covenants and amortization due to complexity of the industry or situation
|
• |
Low debt to asset value and/or enterprise value ratios
|
• |
Financing is typically event driven
|
• |
Companies that are pursuing a merger, acquisition, refinancing, dividend recap, or other strategic liquidity need
|
• |
Companies that are showing strong cash flow performance with low leverage profiles
|
• |
Companies that have multiple areas of value and liquidity in addition to the underlying business
|
• |
Low debt to enterprise value ratios
|
Year
|
Equity (in billions)
|
Debt (in billions)
|
||
2019
|
$4.3
|
$1.1
|
||
2020
|
$1.4
|
$1.3
|
||
2021
|
$5.1
|
$3.8
|
||
2022
|
$1.3
|
$2.0
|
||
2023
|
$0.4
|
$0.6
|
||
2024
|
$0.5
|
$1.2
|
||
Source: Viridian Cannabis Deal Tracker
|
|
Year
|
|
Deals
|
||
2019
|
164
|
|||
2020
|
51
|
|||
2021
|
|
220
|
||
2022
|
109
|
|||
2023
|
|
67
|
||
2024
|
45
|
|||
Source: Viridian Cannabis Deal Tracker
|
• |
The number of years in their current positions;
|
• |
Track record;
|
• |
Industry experience;
|
• |
Management incentive, including the level of direct investment in the enterprise;
|
• |
Background investigations; and
|
• |
Completeness of the management team (lack of positions that need to be filled).
|
• |
Sensitivity to economic cycles;
|
• |
Competitive environment, including number of competitors, threat of new entrants or substitutes;
|
• |
Fragmentation and relative market share of industry leaders;
|
• |
Growth potential; and
|
• |
Regulatory and legal environment.
|
• |
Historical and projected financial performance;
|
• |
Quality of earnings, including source and predictability of cash flows;
|
• |
Customer and vendor interviews and assessments;
|
• |
Potential exit scenarios, including probability of a liquidity event;
|
• |
Internal controls and accounting systems; and
|
• |
Assets, liabilities and contingent liabilities.
|
• |
Investment track record;
|
• |
Industry experience;
|
• |
Capacity and willingness to provide additional financial support to the company through additional capital contributions, if necessary; and
|
• |
Reference checks.
|
• |
Review of monthly and quarterly financial statements and financial projections for portfolio companies;
|
• |
Periodic and regular contact with portfolio company management to discuss financial position requirements and accomplishments;
|
• |
Attendance at board meetings;
|
• |
Periodic formal update interviews with portfolio company management and, if appropriate, the private equity sponsor; and
|
• |
Assessment of business development success, including product development, profitability and the portfolio company’s overall adherence to its business plan.
|
• |
Investments rated 1 involve the least amount of risk to our initial cost basis. The borrower is performing above expectations, and the trends and risk factors for this investment since origination or acquisition are generally favorable.
|
• |
Investments rated 2 involve an acceptable level of risk that is similar to the risk at the time of origination or acquisition. The borrower is generally performing as expected and the risk factors are neutral to favorable. All
investments or acquired investments in new portfolio companies are initially assessed a rating of 2.
|
• |
Investments rated 3 involve a borrower performing below expectations and indicates that the loan’s risk has increased somewhat since origination or acquisition.
|
• |
Investments rated 4 involve a borrower performing materially below expectations and indicates that the loan’s risk has increased materially since origination or acquisition. In addition to the borrower being generally out of compliance
with debt covenants, loan payments may be past due (but generally not more than 120 days past due).
|
• |
Investments rated 5 involve a borrower performing substantially below expectations and indicates that the loan’s risk has increased substantially since origination or acquisition. Most or all of the debt covenants are out of compliance
and payments are substantially delinquent. Loans rated 5 are not anticipated to be repaid in full and we will reduce the fair market value of the loan to the amount we anticipate will be recovered.
|
• |
With respect to investments for which market quotations are readily available, those investments will typically be valued at the bid price of those market quotations;
|
• |
With respect to investments for which market quotations are not readily available, the valuation process begins with the Adviser’s valuation committee establishing a preliminary valuation of each investment, which may be based on
valuations, or ranges of valuations, provided by independent valuation firm(s);
|
• |
Preliminary valuations are documented and discussed by the Adviser’s valuation committee and, where appropriate, the independent valuation firm(s); and
|
• |
The Adviser determines the fair value of each investment.
|
• |
Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;
|
• |
Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active,
or for which all significant inputs are observable, either directly or indirectly; and
|
• |
Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
|
• |
the net asset value of our common stock disclosed in the most recent periodic report that we filed with the SEC;
|
• |
our management’s assessment of whether any material change in the net asset value of our common stock has occurred (including through the realization of gains on the sale of our portfolio securities) during the period beginning on the
date of the most recently disclosed net asset value of our common stock and ending as of a time within 48 hours (excluding Sundays and holidays) of the sale of our common stock; and
|
• |
the magnitude of the difference between (i) a value that our Board of Directors has determined reflects the current (as of a time within 48 hours, excluding Sundays and holidays) net asset value of our common stock, which is based upon
the net asset value of our common stock disclosed in the most recent periodic report that we filed with the SEC, as adjusted to reflect our management’s assessment of any material change in the net asset value of our common stock since the
date of the most recently disclosed net asset value of our common stock, and (ii) the offering price of the shares of our common stock in the proposed offering.
|
• |
Andreas Bodmeier. Dr. Bodmeier served as our Chief Executive Officer from October 2024 until March 2025. Dr. Bodmeier co-founded Chicago Atlantic Group, LP in
April 2019 and has served as Chicago Atlantic Real Estate Finance, Inc.’s Co-President and Chief Investment Officer since its inception in 2021. From October 2019 until December 2020, Dr. Bodmeier was a Senior Advisor to the Deputy
Secretary in the Immediate Office of the Secretary at the United States Department of Health and Human Services focused on policy evaluation and the Department’s response to COVID-19. From June 2015 until March 2019, Dr. Bodmeier was
President of Quantitative Treasury Analytics, LLC, a boutique consulting firm focused on risk management for corporate clients as well as advising on capital structure decisions and investor relations. From May 2017 until March 2019, Dr.
Bodmeier was Co-founder, Chief Investment Officer, and Chief Compliance Officer of Kinetik Finance, Inc., an SEC-registered online investment adviser for 401(k) or 403(b) retirement accounts, where he built the firm’s investment
methodology and compliance program. Dr. Bodmeier has also served as a consultant for hedge funds, proprietary trading firms, commercial and consumer lenders, and pharmaceutical companies. His academic research at The University of Chicago
Booth School of Business focused on capital market anomalies, portfolio allocation, and risk management. Dr. Bodmeier holds a Ph.D. in Finance and MBA from The University of Chicago Booth School of Business. Dr. Bodmeier received a B.Sc.
in Mathematics and a B.Sc. in Physics from Freie University Berlin, Germany, a B.Sc. in Business Economics from University of Hagen, Germany, and a M.Sc. in Statistics from Humboldt University Berlin, Germany.
|
• |
Scott Gordon. Mr. Gordon has served as the Executive Chairman of our Board of Directors since our inception and has served as our Co-Chief Investment Officer
since October 2024. Mr. Gordon served as our Chief Executive Officer from our inception until October 2024. Prior to becoming a Partner at Chicago Atlantic in October 2024 in connection with the Joint Venture, Mr. Gordon was the Chief
Executive Officer of Silver Spike Capital, an investment platform that he founded that was dedicated to the cannabis industry and included our Adviser. Prior to founding Silver Spike Capital, Mr. Gordon had been the co-founder and
chairman of Egg Rock Holdings, LLC (“Egg Rock”), the parent company of the Papa & Barkley family of cannabis products, with related subsidiary assets in manufacturing, processing, and logistics. Egg Rock also is the parent company of
Papa & Barkley Essentials, a hemp-derived CBD business based in Colorado. From 2016 to 2019, Mr. Gordon was also President of Fintech Advisory Inc., the investment manager for a multi-billion dollar family office fund focused on
long-term and opportunistic investments in emerging markets. From late 2013 to 2016, Mr. Gordon served as a Portfolio Manager at Taconic Capital Advisors, a multi-strategy investment firm. Prior to joining Taconic, Mr. Gordon was a
Partner and Portfolio Manager at Caxton Associates from 2009 to 2012. He was also a Senior Managing Director and Head of Emerging Markets at Marathon Asset Management from 2007 to 2009. Earlier in his career, Mr. Gordon held leadership
positions at Bank of America and ING Capital. Mr. Gordon was a founding member of the Emerging Markets business at JP Morgan where he worked upon graduating from Bowdoin College in 1983.
|
• |
Umesh Mahajan. Mr. Mahajan has served as our Secretary since May 2024 and our Co-Chief Investment
Officer since October 2024. Mr. Mahajan served as our Chief Financial Officer from March 2023 until February 2025. Mr. Mahajan also serves as Partner of the Adviser. Prior to joining the Adviser in 2021, Mr. Mahajan was a Managing Director
for four years at Ascribe Capital, a credit fund focused on value investing in middle market companies. From September 2003 to August 2016, Mr. Mahajan worked at Merrill Lynch and Bank of America in various roles in their Global Markets and
Investment Banking divisions in New York. He specialized in credit and special situation investing as a Managing Director in the Global Credit and Special Situations group at Bank of America Securities and as a Vice President in the
Principal Credit Group at Merrill Lynch. Mr. Mahajan also worked in Merrill Lynch’s energy and power investment banking group for two years. From 1994 to 2001, Mr. Mahajan worked in J.P. Morgan’s investment banking team in Asia. Mr. Mahajan
holds a Bachelor of Technology in Electrical Engineering from the Indian Institute of Technology, Bombay and an MBA from The Wharton School of the University of Pennsylvania where he graduated as a Palmer Scholar. Mr. Mahajan also holds a
Certificate in ESG Investing from the CFA Institute.
|
• |
John Mazarakis. Mr. Mazarakis has served as a member of our Board of Directors since October 2024. Mr. Mazarakis co-founded Chicago
Atlantic Group, LP in April 2019 and has served as Chicago Atlantic Real Estate Finance, Inc.’s Executive Chairman since its inception in 2021. As a proven entrepreneur and operator with successful ventures in real estate, retail,
hospitality and food logistics, Mr. Mazarakis brings over 20 years of entrepreneurial, operational, and managerial experience. He has built a 35+ restaurant chain with more than 1,200 employees, established a real estate portfolio of over
30 properties, developed over 1 million square feet of commercial real estate, and completed multiple real estate financing transactions, at a cumulative annual growth rate exceeding 25%. He has invested in and served as an advisor to
multiple successful startups. Mr. Mazarakis has served as a member of the board of directors of Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), a commercial mortgage REIT, since 2021. Mr. Mazarakis has also served as CEO and
Co-Executive Chairman of Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF), a cannabis company, since December 2024. Mr. Mazarakis holds a Bachelor of Arts in Economics from the University of Delaware
and an MBA from The University of Chicago Booth School of Business.
|
• |
Peter Sack. Mr. Sack has served as our Chief Executive Officer since March 2025. Mr.
Sack is a Managing Partner at Chicago Atlantic Group, LP. Mr. Sack is a credit investor and portfolio manager with experience investing across the capital structure. Prior to joining Chicago Atlantic, Mr. Sack was a Principal at BC Partners
Credit from July 2018 to June 2021, where he sourced and underwrote across the firm’s opportunistic and senior lending strategies in a wide array of industries including cannabis-related direct lending. Previously, Mr. Sack was an Associate
at Atlas Holdings LLC, a private-equity firm focused on supporting distressed manufacturing and distribution companies globally, from July 2012 to June 2016. Mr. Sack serves on the boards of directors of Chicago Atlantic Real Estate
Finance, Inc., Ability Insurance Company, and the New York City Charter School of the Arts. Mr. Sack speaks Mandarin Chinese and Spanish. Mr. Sack holds a Bachelor of Arts degree in East Asian Studies from Yale University, and a Master of
Business Administration degree from the Wharton School of the University of Pennsylvania, and was a Fulbright Scholar at Sun Yat-sen University in China.
|
• |
determines the composition of our portfolio, the nature and timing of the changes to our portfolio and the manner of implementing such changes;
|
• |
determines what securities and other assets we purchase, retain or sell;
|
• |
identifies, evaluates and negotiates the structure of the investments we make;
|
• |
executes, monitors and services the investments we make;
|
• |
performs due diligence on prospective portfolio companies; and
|
• |
provides us with such other investment advisory, research and related services as we may, from time to time, reasonably require for the investment of our funds, including providing operating and managerial assistance to us and our
portfolio companies as required.
|
• |
No Incentive Fee on Income is payable to the Adviser in any quarter in which our Pre-Incentive Fee Net Investment Income does not exceed the “hurdle rate” of 1.75%;
|
• |
100% of our Pre-Incentive Fee Net Investment Income, if any, that exceeds the “hurdle rate,” but is less than or equal to 2.19% in any quarter (8.76% annualized), will be payable to the Adviser. We refer to this portion of our Incentive
Fee on Income as the catch up. It is intended to provide an Incentive Fee on Income of 20% on all of our Pre-Incentive Fee Net Investment Income when our Pre-Incentive Fee Net Investment Income exceeds 2.19% in any quarter;
|
• |
For any quarter in which our Pre-Incentive Fee Net Investment Income exceeds 2.19%, the Incentive Fee on Income shall equal 20% of the amount of our Pre-Incentive Fee Net Investment Income, because the preferred return and catch up will
have been achieved; and
|
• |
For purposes of computing the Incentive Fee on Income, the calculation methodology will look through derivatives or swaps as if we owned the reference assets directly. Therefore, net interest income, if any, associated with a derivative
or swap (which is defined as the difference between (i) the interest income and transaction fees received in respect of the reference assets of the derivative or swap and (ii) all interest and other expenses paid by us to the derivative or
swap counterparty) will be included in the calculation of Pre-Incentive Fee Net Investment Income for purposes of the Incentive Fee on Income.
|
(1) |
Represents 7% annualized hurdle rate.
|
(2) |
Represents 1.75% annualized base management fee.
|
(3) |
The “catch-up” provision is intended to provide our Adviser with an Incentive Fee on Income of 20% on all Pre-Incentive Fee Net Investment Income as if a hurdle rate did not apply when our Pre-Incentive Fee Net Investment Income exceeds
2.19% in any quarter.
|
Year 1:
|
$20 million investment made in Company A (“Investment A”) and $30 million investment made in Company B (“Investment B”)
|
Year 2: |
Investment A sold for $50 million and fair market value (“FMV”) of Investment B determined to be $32 million
|
Year 3: |
FMV of Investment B determined to be $25 million
|
Year 4: |
Investment B sold for $31 million
|
Year 1: |
None
|
Year 2: |
Incentive Fee on Capital Gains of $6 million — ($30 million realized capital gains on sale of Investment A multiplied by 20%)
|
Year 3: |
None — $5 million (20% multiplied by ($30 million cumulative capital gains less $5 million cumulative capital depreciation)) less $6 million (Incentive Fee on Capital Gains paid in Year 2)
|
Year 4: |
Incentive Fee on Capital Gains of $200,000 — $6.2 million ($31 million cumulative realized capital gains multiplied by 20%) less $6 million (Incentive Fee on Capital Gains paid in Year 2)
|
Year 1: |
$20 million investment made in Company A (“Investment A”), $30 million investment made in Company B (“Investment B”) and $25 million investment made in Company C (“Investment C”)
|
Year 2: |
Investment A sold for $50 million, FMV of Investment B determined to be $25 million and FMV of Investment C determined to be $25 million
|
Year 3: |
FMV of Investment B determined to be $27 million and Investment C sold for $30 million
|
Year 4: |
FMV of Investment B determined to be $24 million
|
Year 5: |
Investment B sold for $20 million
|
Year 1: |
None
|
Year 2: |
$5 million Incentive Fee on Capital Gains — 20% multiplied by $25 million ($30 million realized capital gains on Investment A less $5 million unrealized capital depreciation on Investment B)
|
Year 3: |
$1.4 million Incentive Fee on Capital Gains(1) — $6.4 million (20% multiplied by $32 million ($35 million cumulative realized capital gains less $3 million unrealized capital depreciation on Investment B)) less $5 million (Incentive Fee
on Capital Gains paid in Year 2)
|
Year 4: |
None
|
Year 5: |
None — $5 million (20% multiplied by $25 million (cumulative realized capital gains of $35 million less realized capital losses of $10 million)) less $6.4 million (cumulative Incentive Fees on Capital Gains paid in Year 2 and Year 3)(2)
|
(1) |
As illustrated in Year 3 of Scenario 2 above, if we were to be wound up on a date other than our fiscal year end of any year, we may have paid aggregate Incentive Fees on Capital Gains that are more than the amount of such fees that
would be payable if we had been wound up on our fiscal year end of such year.
|
(2) |
As noted above, it is possible that the cumulative aggregate Incentive Fees on Capital Gains received by our Adviser ($6.4 million) is effectively greater than $5 million (20% of cumulative aggregate realized capital gains less net
realized capital losses or net unrealized depreciation ($25 million)).
|
• |
the cost of our organization and offerings;
|
• |
the cost of calculating our NAV, including the cost of any third-party valuation services;
|
• |
the cost of effecting sales and repurchases of shares of our common stock and other securities;
|
• |
fees and expenses payable under any underwriting agreements, if any;
|
• |
debt service and other costs of borrowings or other financing arrangements;
|
• |
costs of hedging;
|
• |
expenses, including travel expenses, incurred by the Adviser, or members of the investment team, or payable to third-parties, performing due diligence on prospective portfolio companies and, if necessary, enforcing our rights;
|
• |
management and incentive fees payable pursuant to the Investment Advisory Agreement;
|
• |
fees payable to third-parties relating to, or associated with, making investments and valuing investments (including third-party valuation firms);
|
• |
costs, including legal fees, associated with compliance under cannabis laws;
|
• |
transfer agent and custodial fees;
|
• |
fees and expenses associated with marketing efforts (including attendance at industry and investor conferences and similar events);
|
• |
federal and state registration fees;
|
• |
any exchange listing fees and fees payable to rating agencies;
|
• |
federal, state and local taxes;
|
• |
independent directors’ fees and expenses, including travel expenses;
|
• |
cost of preparing financial statements and maintaining books and records and filing reports or other documents with the SEC (or other regulatory bodies) and other reporting and compliance costs, and the compensation of professionals
responsible for the preparation of the foregoing;
|
• |
the cost of any reports, proxy statements or other notices to our stockholders (including printing and mailing costs), the costs of any stockholder or director meetings and the compensation of investor relations personnel responsible for
the preparation of the foregoing and related matters;
|
• |
brokerage commissions and other compensation payable to brokers or dealers;
|
• |
research and market data;
|
• |
fidelity bond, directors’ and officers’ errors and omissions liability insurance and other insurance premiums;
|
• |
direct costs and expenses of administration, including printing, mailing and staff;
|
• |
fees and expenses associated with independent audits, and outside legal and consulting costs;
|
• |
costs of winding up;
|
• |
costs incurred in connection with the formation or maintenance of entities or vehicles to hold our assets for tax or other purposes;
|
• |
extraordinary expenses (such as litigation or indemnification); and
|
• |
costs associated with reporting and compliance obligations under the 1940 Act and applicable federal and state securities laws.
|
● |
the nature, quality and extent of the advisory and other services to be provided to the Company by the Adviser;
|
● |
comparative data with respect to advisory fees or similar expenses paid by other BDCs with similar investment objectives;
|
● |
the Company’s projected operating expenses and expense ratio compared to BDCs with similar investment objectives;
|
● |
any existing and potential sources of indirect income to the Adviser from its relationships with the Company and the profitability of those relationships;
|
● |
information about the services to be performed and the personnel performing such services under the Investment Advisory Agreement; and
|
● |
the organizational capability and financial condition of the Adviser and its affiliates.
|
● |
the last day of the first fiscal year in which our annual gross revenues exceed $1.235 billion;
|
● |
the last day of the fiscal year that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act which would occur if the market value of the shares of our common stock that is held by non-affiliates exceeds
$700.0 million as of the last business day of our most recently completed second fiscal quarter and we have been publicly reporting for at least 12 months; or
|
● |
the date on which we have issued more than $1.0 billion in non-convertible debt securities during the preceding three-year period.
|
(1) |
Securities purchased in transactions not involving any public offering from the issuer of such securities, which issuer (subject to certain limited exceptions) is an eligible portfolio company, or from any person who is, or has been
during the preceding 13 months, an affiliated person of an eligible portfolio company, or from any other person, subject to such rules as may be prescribed by the SEC. An eligible portfolio company is defined in the 1940 Act as any issuer
which:
|
(a) |
is organized under the laws of, and has its principal place of business in, the United States;
|
(b) |
is not an investment company (other than a small business investment company wholly owned by the BDC) or a company that would be an investment company but for certain exclusions under the 1940 Act; and
|
(c) |
satisfies any of the following:
|
(i) |
does not have any class of securities that is traded on a national securities exchange;
|
(ii) |
has a class of securities listed on a national securities exchange, but has an aggregate market value of outstanding voting and non-voting common equity of less than $250 million;
|
(iii) |
is controlled by a BDC or a group of companies including a BDC and the BDC has an affiliated person who is a director of the eligible portfolio company; or
|
(iv) |
is a small and solvent company having total assets of not more than $4 million and capital and surplus of not less than $2 million.
|
(2) |
Securities of any eligible portfolio company that we control.
|
(3) |
Securities purchased in a private transaction from a U.S. issuer that is not an investment company or from an affiliated person of the issuer, or in transactions incident thereto, if the issuer is in bankruptcy and subject to
reorganization or if the issuer, immediately prior to the purchase of its securities was unable to meet its obligations as they came due without material assistance other than conventional lending or financing arrangements.
|
(4) |
Securities of an eligible portfolio company purchased from any person in a private transaction if there is no ready market for such securities and we already own 60% of the outstanding equity of the eligible portfolio company.
|
(5) |
Securities received in exchange for or distributed on or with respect to securities described in (1) through (4) above, or pursuant to the exercise of warrants or rights relating to such securities.
|
(6) |
Cash, cash equivalents, U.S. government securities or high-quality debt securities maturing in one year or less from the time of investment.
|
• |
pursuant to Rule 13a-14 of the Exchange Act, our chief executive officer and chief financial officer are required to certify the accuracy of the financial statements contained in our periodic reports;
|
• |
pursuant to Item 307 of Regulation S-K, our periodic reports are required to disclose our conclusions about the effectiveness of our disclosure controls and procedures; and
|
• |
pursuant to Rule 13a-15 of the Exchange Act, our management is required to prepare a report regarding its assessment of our internal control over financial reporting. When we are no longer an emerging growth company under the JOBS Act,
our independent registered public accounting firm will be required to audit our internal control over financial reporting.
|
• |
certain financial institutions;
|
• |
regulated investment companies;
|
• |
real estate investment trusts;
|
• |
dealers or traders in securities that use a mark-to-market method of tax accounting;
|
• |
persons holding shares of our common stock as part of a straddle, wash sale, conversion transaction or integrated transaction or persons entering into a constructive sale with respect to the shares;
|
• |
U.S. Holders (as defined below) whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;
|
• |
entities classified as partnerships or otherwise treated as pass-through entities for U.S. federal income tax purposes;
|
• |
certain former U.S. citizens and residents and expatriated entities;
|
• |
tax-exempt entities, including an “individual retirement account” or “Roth IRA”; or
|
• |
insurance companies.
|
• |
Economic recessions or downturns may have a material adverse effect on our business, financial condition and results of operations, and could impair the ability of our portfolio companies to repay debt or pay interest.
|
• |
Global economic, political and market conditions, including those caused by the current public health crisis, have (and in the future, could further) adversely affect our business, results of operations and financial condition and those
of our portfolio companies.
|
• |
We have limited operating history and our Adviser is a recently registered investment adviser under the Advisers Act, with limited history of managing BDCs and limited history of making credit investments in the nascent cannabis
industry.
|
• |
Our investment portfolio will be recorded at fair value as determined in good faith in accordance with procedures established by our Board of Directors and, as a result, there will be uncertainty as to the value of our portfolio
investments.
|
• |
Our ability to achieve our investment objective depends on our Adviser’s ability to support our investment process; if our Adviser were to lose key personnel or they were to resign, our ability to achieve our investment objective could
be significantly harmed.
|
• |
Our business model depends to a significant extent upon strong referral relationships, and the inability of the personnel associated with our Adviser to maintain or develop these relationships, or the failure of these relationships to
generate investment opportunities, could adversely affect our business.
|
• |
A failure on our part to maintain qualification as a BDC would significantly reduce our operating flexibility.
|
• |
Regulations governing our operation as a BDC and RIC may affect our ability to raise, and the way in which we raise, additional capital or borrow for investment purposes, which may have a negative effect on our growth.
|
• |
Changes in laws or regulations governing our operations, including laws and regulations governing cannabis, may adversely affect our business or cause us to alter our business strategy.
|
• |
Provisions of the Maryland General Corporation Law and of our charter and bylaws could deter takeover attempts and have an adverse impact on the price of our common stock.
|
• |
We may be unable to invest a significant portion of the net proceeds from our initial public offering, or any follow-on offering of shares of our common stock, on acceptable terms within an attractive time frame.
|
• |
Because we intend to distribute at least 90% of our taxable income each taxable year to our stockholders in connection with our election to be treated as a RIC, we will continue to need additional capital to finance our growth.
|
• |
We may not be able to pay you distributions, and if we are able to pay you distributions, our distributions may not grow over time and/or a portion of our distributions may be a return of capital. We have not established any limit on the
extent to which we may use offering proceeds to fund distributions.
|
• |
We will be subject to corporate-level U.S. federal income tax if we are unable to obtain and maintain qualification as a RIC under Subchapter M of the Code or do not satisfy the annual distribution requirement.
|
• |
Our investments in portfolio companies may be risky, and we could lose all or part of our investments.
|
• |
We intend to invest primarily in securities that are rated below investment grade by rating agencies or that would be rated below investment grade if they were rated. Below investment grade securities, which
are often referred to as “junk,” have predominantly speculative characteristics with respect to the issuer’s capacity to pay interest and return principal. They may also be illiquid and difficult to value.
|
• |
Some of the loans in which we may invest may be “covenant-lite” loans, which may have a greater risk of loss as compared to investments in or exposure to loans with a complete set of financial maintenance
covenants.
|
• |
The lack of liquidity in our investments may adversely affect our business.
|
• |
Shares of closed-end investment companies, including BDCs, may trade at a discount to their net asset value (“NAV”).
|
• |
The market price of our common stock may fluctuate significantly.
|
• |
Cannabis, except for hemp, is currently illegal under U.S. federal law and in other jurisdictions, and strict enforcement of federal laws would likely result in our inability to execute our business plan.
|
• |
Loans to relatively new and/or small companies and companies operating in the cannabis industry generally involve significant risks.
|
• |
Our investment opportunities are limited by the current illegality of cannabis under U.S. federal law, and change in the laws, regulations and guidelines that impact the cannabis industry may cause adverse effects on our ability to make
investments.
|
• |
Strict enforcement of U.S. federal laws regarding cannabis would likely result in our portfolio companies’ inability to execute a business plan in the cannabis industry, and could result in the loss of all or part of any of our loans.
|
• |
The nascent status of the medical and recreational cannabis industry involves unique circumstances and there can be no assurance that the industry will continue to exist or grow as currently anticipated.
|
• |
Any potential growth in the cannabis industry continues to be subject to new and changing state and local laws and regulations.
|
• |
Portfolio companies may have difficulty borrowing from or otherwise accessing the service of banks, which may make it difficult to sell products and services.
|
• |
We, portfolio companies or the cannabis industry more generally may receive unfavorable publicity or become subject to negative consumer or investor perception.
|
• |
Third-parties with whom we do business may perceive themselves as being exposed to reputational risk by virtue of their relationship with us and may ultimately elect not to do business with us.
|
• |
Portfolio companies may be subject to regulatory, legal or reputational risk associated with potential misuse of their products by their customers.
|
• |
There may be a lack of access to U.S. bankruptcy protections for portfolio companies.
|
• |
U.S. federal courts may refuse to recognize the enforceability of contracts pertaining to any business operations that are deemed illegal under U.S. federal law, including cannabis companies operating legally under state law.
|
• |
Cybersecurity risks and cyber incidents may adversely affect our business or the business of our portfolio companies by causing a disruption to our operations or the operations of our portfolio companies, a
compromise or corruption of our confidential information or the confidential information of our portfolio companies and/or damage to our business relationships or the business relationships of our portfolio companies, all of which could
negatively impact the business, financial condition and operating results of us or our portfolio companies.
|
• |
Sales of shares of our common stock after the completion of the Loan Portfolio Acquisition may cause the market price of our common stock to decline.
|
• |
We may be unable to realize the benefits anticipated by the Loan Portfolio Acquisition, including estimated cost savings, or it may take longer than anticipated to achieve such benefits.
|
• |
sudden electrical or telecommunications outages;
|
• |
natural disasters such as earthquakes, tornadoes and hurricanes;
|
• |
disease pandemics;
|
• |
events arising from local or larger scale political or social matters, including terrorist acts; and
|
• |
cyber-attacks.
|
• |
The annual distribution requirement will be satisfied if we distribute to our stockholders each taxable year an amount generally at least equal to 90% of the sum of our net taxable income plus realized net short-term capital gains in
excess of realized net long-term capital losses, if any. Because we may use debt financing, we are subject to an asset coverage ratio requirement under the 1940 Act and we may be subject to certain financial covenants under our debt
arrangements that could, under certain circumstances, restrict us from making distributions necessary to satisfy the annual distribution requirement. If we are unable to obtain cash from other sources, we could fail to qualify for RIC tax
treatment and thus could become subject to corporate-level income tax.
|
• |
The 90% gross income test will be satisfied if we earn at least 90% of our gross income for each taxable year from dividends, interest, gains from the sale of stock or securities or similar sources.
|
• |
The diversification test will be satisfied if, at the end of each quarter of our taxable year, at least 50% of the value of our assets consist of cash, cash equivalents, U.S. government securities, securities of other RICs, and other
acceptable securities; and no more than 25% of the value of our assets can be invested in the securities, other than U.S. government securities or securities of other RICs, of one issuer, of two or more issuers that are controlled, as
determined under applicable Code rules, by us and that are engaged in the same or similar or related trades or businesses or of certain “qualified publicly traded partnerships.” Failure to meet these requirements may result in our having to
dispose of certain investments quickly in order to prevent the loss of RIC status. Because most of our investments will be in private companies, and therefore will be relatively illiquid, any such dispositions could be made at
disadvantageous prices and could cause us to incur substantial losses.
|
• |
may have limited financial resources, may have limited or negative EBITDA and may be unable to meet their obligations under their debt instruments that we hold, which may be accompanied by a deterioration in the value of any collateral
and a reduction in the likelihood of us realizing any guarantees from subsidiaries or affiliates of our portfolio companies that we may have obtained in connection with our investments, as well as a corresponding decrease in the value of
the equity components of our investments;
|
• |
may have shorter operating histories, narrower product lines, smaller market shares and/or significant customer concentrations than larger businesses, which tend to render them more vulnerable to competitors’ actions and market
conditions, as well as general economic downturns;
|
• |
may operate in regulated industries and/or provide services to federal, state or local governments, or operate in industries that provide services to regulated industries or federal, state or local governments, any of which could lead to
delayed payments for services or subject the company to changing payment and reimbursement rates or other terms;
|
• |
may not have collateral sufficient to pay any outstanding interest or principal due to us in the event of a default by these companies;
|
• |
are more likely to depend on the management talents and efforts of a small group of people; therefore, the death, disability, resignation or termination of one or more of these persons could have a material adverse impact on our
portfolio company and, in turn, on us;
|
• |
may have difficulty borrowing or otherwise accessing the capital markets to fund capital needs, which may be more acute because such companies are operating in the cannabis industry, and which limit their ability to grow or repay
outstanding indebtedness at maturity (see “— Risks Related to the Cannabis and Hemp Industries” below);
|
• |
may not have audited financial statements or be subject to the Sarbanes-Oxley Act and other rules that govern public companies;
|
• |
generally have less predictable operating results, may from time to time be parties to litigation, may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence, and may require substantial
additional capital to support their operations, finance expansion or maintain their competitive position; and
|
• |
generally have less publicly available information about their businesses, operations and financial condition.
|
• |
OID and PIK instruments may have higher yields, which reflect the payment deferral and credit risk associated with these instruments;
|
• |
OID and PIK accruals may create uncertainty about the source of our distributions to stockholders;
|
• |
OID and PIK instruments may have unreliable valuations because their continuing accruals require continuing judgments about the collectability of the deferred payments and the value of the collateral;
|
• |
OID and PIK instruments may represent a higher credit risk than coupon loans; and
|
• |
Our net investment income used to calculate the Incentive Fee on Income will include OID and PIK interest, and the Adviser is not obligated to return the Incentive Fee on Income it receives on OID and PIK interest that is later
determined to be uncollectible in cash.
|
• |
The cannabis industry is extremely speculative and raises a host of legality issues, making it subject to inherent risk;
|
• |
The manufacture, distribution, sale, or possession of cannabis that is not in compliance with the U.S. Controlled Substances Act is illegal under U.S. federal law. Strict enforcement of U.S. federal laws regarding cannabis would likely
result in our portfolio companies’ inability to execute a business plan in the cannabis industry, and could result in the loss of all or part of any of our loans;
|
• |
The current Presidential Administration’s or specifically the U.S. Department of Justice’s change in policies or enforcement with respect to U.S. federal cannabis laws could negatively impact our portfolio companies’ ability to pursue
their prospective business operations and/or generate revenues;
|
• |
U.S. federal courts may refuse to recognize the enforceability of contracts pertaining to any business operations that are deemed illegal under U.S. federal law, including cannabis companies operating legally under state law;
|
• |
Consumer complaints and negative publicity regarding cannabis-related products and services could lead to political pressure on states to implement new laws and regulations that are adverse to the cannabis industry, to not modify
existing, restrictive laws and regulations, or to reverse current favorable laws and regulations relating to cannabis;
|
• |
Assets collateralizing loans to cannabis businesses may be forfeited to the U.S. federal government in connection with government enforcement actions under U.S. federal law;
|
• |
U.S. Food and Drug Administration regulation of cannabis and the possible registration of facilities where cannabis is grown could negatively affect the cannabis industry, which could directly affect our financial condition and the
financial condition of our portfolio companies;
|
• |
Due to our proposed strategy of investing in portfolio companies engaged in the regulated cannabis industry, our portfolio companies may have a difficult time obtaining the various insurance policies that are needed to operate such
businesses, which may expose us and our portfolio companies to additional risks and financial liabilities;
|
• |
The cannabis industry may face significant opposition from other industries that perceive cannabis products and services as competitive with their own, including but not limited to the pharmaceutical industry, adult beverage industry and
tobacco industry, all of which have powerful lobbying and financial resources;
|
• |
Many national and regional banks have been resistant to doing business with cannabis companies because of the uncertainties presented by federal law and, as a result, we or our portfolio companies may have difficulty borrowing from or
otherwise accessing the service of banks, which may inhibit our ability to open bank accounts or otherwise utilize traditional banking services;
|
• |
Due to our proposed strategy of investing in portfolio companies engaged in the regulated cannabis industry, we or our portfolio companies may have a difficult time obtaining financing in connection with our investment strategy; and
|
• |
Laws and regulations affecting the regulated cannabis industry are varied, broad in scope and subject to evolving interpretations, and may restrict the use of the properties our portfolio companies acquire or require certain additional
regulatory approvals, which could materially adversely affect our investments in such portfolio companies.
|
• |
these companies may have limited financial resources and may be unable to meet their obligations, which may be accompanied by a deterioration in the value of any collateral securing our loan and a reduction in the likelihood of us
realizing a return on our loan;
|
• |
they typically have shorter operating histories, narrower product lines and smaller market shares than larger and more established businesses, which tend to render them more vulnerable to competitors’ actions and market conditions
(including conditions in the cannabis industry), as well as general economic downturns;
|
• |
they typically depend on the management talents and efforts of a small group of persons; therefore, the death, disability, resignation or termination of one or more of these persons could have a material adverse effect on such borrower
and, in turn, on us;
|
• |
there is generally less public information about these companies. Unless publicly traded, these companies and their financial information are generally not subject to the regulations that govern public companies, and we may be unable to
uncover all material information about these companies, which may prevent us from making a fully informed lending decision and cause us to lose money on our loans;
|
• |
they generally have less predictable operating results and may require substantial additional capital to support their operations, finance expansion or maintain their competitive position;
|
• |
we, our executive officers and directors and our Adviser may, in the ordinary course of business, be named as defendants in litigation arising from our loans to such borrowers and may, as a result, incur significant costs and expenses in
connection with such litigation;
|
• |
changes in laws and regulations, as well as their interpretations, may have a disproportionate adverse effect on their business, financial structure or prospects compared to those of larger and more established companies; and
|
• |
they may have difficulty accessing capital from other providers on favorable terms or at all.
|
• |
significant volatility in the market price and trading volume of securities of BDCs or other companies in our sector, which are not necessarily related to the operating performance of these companies;
|
• |
inability to obtain any exemptive relief that may be required by us from the SEC, if any;
|
• |
changes in regulatory policies, accounting pronouncements or tax guidelines, particularly with respect to RICs and BDCs;
|
• |
loss of our BDC or RIC status;
|
• |
changes in earnings or variations in operating results or distributions that exceed our net investment income;
|
• |
increases in expenses associated with defense of litigation and responding to SEC inquiries;
|
• |
changes in accounting guidelines governing valuation of our investments;
|
• |
changes in the value of our portfolio of investments and any derivative instruments, including as a result of general economic conditions, interest rate shifts and changes in the performance of our portfolio companies;
|
• |
any shortfall in investment income or net investment income or any increase in losses from levels expected by investors or securities analysts;
|
• |
sales of our common stock by the Adviser or CALP;
|
• |
departure of our Adviser’s key personnel; and
|
• |
general economic trends and other external factors.
|
Item 5.
|
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
|
Class and Period
|
Net Asset
Value(1)
|
|
|
High Sales
Price
Premium
(Discount)
to Net Asset
Value(2)
|
Low Sales
Price
Premium
(Discount) to
Net Asset
Value(2) |
Cash
Dividend
Per Share(3)
|
|||||||||||||||||||
Price Range | |||||||||||||||||||||||||
High | Low | ||||||||||||||||||||||||
Year Ended December 31, 2025
|
|||||||||||||||||||||||||
First Quarter (Through March 28, 2025)
|
*
|
$ |
12.56
|
$ |
10.92
|
*
|
*
|
$ | 0.34 |
(6) | |||||||||||||||
Year Ended December 31, 2024
|
|||||||||||||||||||||||||
Fourth Quarter
|
$ |
13.20
|
$ |
13.24
|
$ |
10.74
|
0.3
|
%
|
-18.7
|
%
|
$ |
0.34
|
|||||||||||||
Third Quarter
|
$ |
13.28
|
$ |
12.00
|
$ |
10.64
|
-9.6
|
%
|
-19.9
|
%
|
$ |
0.25
|
|||||||||||||
Second Quarter
|
$ |
13.56
|
$ |
12.38
|
$ |
9.61
|
-8.7
|
%
|
-29.1
|
%
|
$ |
0.25
|
|||||||||||||
First Quarter
|
$ |
13.60
|
$ |
10.28
|
$ |
7.65
|
-24.4
|
%
|
-43.8
|
%
|
$ |
0.25
|
|||||||||||||
Year Ended December 31, 2023
|
|||||||||||||||||||||||||
Fourth Quarter
|
$ |
13.77
|
$ |
9.81
|
$ |
8.32
|
-28.8
|
%
|
-39.6
|
%
|
$ |
0.70
|
(7)
|
||||||||||||
Third Quarter
|
$ |
14.06
|
$ |
10.37
|
$ |
7.65
|
-26.3
|
%
|
-45.6
|
%
|
$ |
0.63
|
(7)
|
||||||||||||
Second Quarter
|
$ |
14.49
|
$ |
9.19
|
$ |
7.82
|
-36.3
|
%
|
-45.8
|
%
|
-
|
||||||||||||||
First Quarter
|
$ |
14.29
|
$ |
9.98
|
$ |
8.25
|
-30.2
|
%
|
-42.3
|
%
|
-
|
||||||||||||||
Year Ended December 31, 2022(4)
|
|||||||||||||||||||||||||
Fourth Quarter
|
$ |
13.91
|
$ |
10.55
|
$ |
9.57
|
-24.2
|
%
|
-31.2
|
%
|
-
|
||||||||||||||
Third Quarter
|
$ |
13.73
|
$ |
10.74
|
$ |
9.00
|
-21.8
|
%
|
-34.5
|
%
|
-
|
||||||||||||||
Second Quarter
|
$ |
13.64
|
$ |
13.50
|
|
$ |
7.80
|
-1.0
|
%
|
-42.8
|
%
|
-
|
|||||||||||||
First Quarter(5)
|
$ |
13.61
|
$ |
14.41
|
$ |
12.57
|
5.9
|
%
|
-7.6
|
%
|
-
|
(1) |
Net asset value per share is determined as of the last day in the relevant quarter and therefore may not reflect the net asset value per share on the date of the high and low closing sales prices. The net
asset values shown are based on outstanding shares at the end of the relevant quarter.
|
(2) |
Calculated as the respective high or low closing sales price less net asset value, divided by net asset value (in each case, as of the end of the applicable quarter).
|
(3) |
Represents the dividend or distribution declared in the relevant quarter.
|
(4) |
On November 8, 2022, our Board of Directors approved a change to our fiscal year end from March 31 to December 31.
|
(5) |
Shares of our common stock began trading on the Nasdaq Global Market on February 4, 2022. Since October 2, 2024, our
common stock trades on the Nasdaq Global Market under the symbol “LIEN.”
|
(6) |
The dividend is payable on April 11, 2025 to stockholders of record on March 28, 2025.
|
(7) |
Consists of a quarterly dividend and a special dividend.
|
* |
Not determined at time of filing.
|
Declaration Date
|
Type
|
Record Date
|
Payment Date
|
Per Share Amount
|
Dividends
Paid
|
|||||||||
August 10, 2023
|
Quarterly
|
September 15, 2023
|
September 29, 2023
|
$
|
0.23
|
$
|
1,429,375
|
|||||||
August 10, 2023
|
Special
|
September 15, 2023
|
September 29, 2023
|
$
|
0.40
|
$
|
2,485,869
|
|||||||
November 9, 2023
|
Quarterly
|
December 20, 2023
|
December 29, 2023
|
$
|
0.25
|
$
|
1,553,676
|
|||||||
November 9, 2023
|
Special
|
December 20, 2023
|
December 29, 2023
|
$
|
0.45
|
$
|
2,796,617
|
|||||||
March 8, 2024
|
Quarterly
|
March 20, 2024
|
March 28, 2024
|
$
|
0.25
|
$
|
1,553,736
|
|||||||
May 9, 2024
|
Quarterly
|
June 20, 2024
|
June 28, 2024
|
$
|
0.25
|
$
|
1,553,738
|
|||||||
August 8, 2024
|
Quarterly
|
September 19, 2024
|
September 27, 2024
|
$
|
0.25
|
$
|
1,553,741
|
|||||||
December 9, 2024
|
Quarterly
|
December 19, 2024
|
December 27, 2024
|
$
|
0.34
|
$
|
7,758,925
|
Declaration Date
|
Type
|
Record Date
|
Payment Date
|
Shares
|
||||
March 8, 2024
|
|
Quarterly
|
|
March 20, 2024
|
|
March 28, 2024
|
|
8
|
May 9, 2024
|
Quarterly
|
June 20, 2024
|
June 28, 2024
|
15
|
||||
August 8, 2024
|
|
Quarterly
|
|
September 19, 2024
|
|
September 27, 2024
|
|
31
|
December 9, 2024
|
Quarterly
|
December 19, 2024
|
December 27, 2024
|
19
|
Declaration Date
|
Type
|
Record Date
|
Payment Date
|
Shares
|
||||
August 10, 2023
|
|
Quarterly
|
|
September 15, 2023
|
|
September 29, 2023
|
|
12
|
August 10, 2023
|
Special
|
September 15, 2023
|
September 29, 2023
|
21
|
||||
November 9, 2023
|
|
Quarterly
|
|
December 20, 2023
|
|
December 29, 2023
|
|
84
|
November 9, 2023
|
Special
|
December 20, 2023
|
December 29, 2023
|
152
|
• |
Growth or EBITDA positive entities
|
• |
Companies that require capital but do not want to dilute their equity
|
• |
Companies that are showing strong cash flow performance with low leverage profiles
|
• |
Transactions that tend to be attractively priced and have better than normal covenants and amortization due to complexity of the industry
|
• |
Low debt to enterprise value
|
• |
Industry leaders and disruptive companies experiencing strong growth
|
• |
Companies that have raised significant equity capital validating market value
|
• |
Industry focus typically includes software, hardware, e-commerce, direct to consumer and other fast-growing companies
|
• |
Liquidity covenants that ensure such company has adequate cash runway
|
• |
Low debt to enterprise value
|
• |
Profitable or demonstrated path to near term profitability
|
• |
Companies that are showing strong cash flow performance with low leverage profiles, but the industries carry regulatory, reputational or other risks
|
• |
Companies with attractive assets, including, but not limited to, accounts receivable, equipment or real estate
|
• |
Transactions that tend to be attractively priced and have better than normal covenants and amortization due to complexity of the industry or situation
|
• |
Low debt to asset value and/or enterprise value ratios
|
•
|
Financing is typically event driven
|
• |
Companies that are pursuing a merger, acquisition, refinancing, dividend recap, or other strategic liquidity need
|
• |
Companies that are showing strong cash flow performance with low leverage profiles
|
• |
Companies that have multiple areas of value and liquidity in addition to the underlying business
|
• |
Low debt to enterprise value ratios
|
• |
the cost of our organization and offerings;
|
• |
the cost of calculating our NAV, including the cost of any third-party valuation services;
|
• |
the cost of effecting sales and repurchases of shares of our common stock and other securities;
|
• |
fees and expenses payable under any underwriting agreements, if any;
|
• |
debt service and other costs of borrowings or other financing arrangements;
|
• |
costs of hedging;
|
• |
expenses, including travel expenses, incurred by the Adviser, or members of the investment team, or payable to third-parties, performing due diligence on prospective portfolio companies and, if necessary,
enforcing our rights;
|
• |
management and incentive fees payable pursuant to the Investment Advisory Agreement;
|
• |
fees payable to third-parties relating to, or associated with, making investments and valuing investments (including third-party valuation firms);
|
• |
costs, including legal fees, associated with compliance under cannabis laws;
|
• |
transfer agent and custodial fees;
|
• |
fees and expenses associated with marketing efforts (including attendance at industry and investor conferences and similar events);
|
• |
federal and state registration fees;
|
• |
any exchange listing fees and fees payable to rating agencies;
|
• |
federal, state and local taxes;
|
• |
independent directors’ fees and expenses, including travel expenses;
|
• |
cost of preparing financial statements and maintaining books and records and filing reports or other documents with the SEC (or other regulatory bodies) and other reporting and compliance costs, and the
compensation of professionals responsible for the preparation of the foregoing;
|
• |
the cost of any reports, proxy statements or other notices to our stockholders (including printing and mailing costs), the costs of any stockholder or director meetings and the compensation of investor
relations personnel responsible for the preparation of the foregoing and related matters;
|
• |
brokerage commissions and other compensation payable to brokers or dealers;
|
• |
research and market data;
|
• |
fidelity bond, directors’ and officers’ errors and omissions liability insurance and other insurance premiums;
|
• |
direct costs and expenses of administration, including printing, mailing and staff;
|
• |
fees and expenses associated with independent audits, and outside legal and consulting costs;
|
• |
costs of winding up;
|
• |
costs incurred in connection with the formation or maintenance of entities or vehicles to hold our assets for tax or other purposes;
|
• |
extraordinary expenses (such as litigation or indemnification); and
|
• |
costs associated with reporting and compliance obligations under the 1940 Act and applicable federal and state securities laws.
|
As of December 31, 2024
|
||||||||
Type
|
Amortized Cost
|
Fair Value
|
||||||
First Lien Senior Secured Loans
|
87.1
|
%
|
87.1
|
%
|
||||
Senior Secured Notes
|
12.6
|
12.6
|
||||||
Preferred Stock
|
0.2
|
0.2
|
||||||
Warrants
|
0.1
|
0.1
|
||||||
Total
|
100.0
|
%
|
100.0
|
%
|
As of December 31, 2023
|
||||||||
Type
|
Amortized Cost
|
Fair Value
|
||||||
First Lien Senior Secured Loans
|
84.9
|
%
|
85.0
|
%
|
||||
Senior Secured Notes
|
15.1
|
15.0
|
||||||
Total
|
100.0
|
%
|
100.0
|
%
|
As of December 31, 2024
|
||||||||
Geographic Region
|
Amortized Cost
|
Fair Value
|
||||||
United States:
|
||||||||
Midwest
|
32.4
|
%
|
32.6
|
%
|
||||
West
|
31.6
|
|
31.5
|
|
||||
Northeast
|
19.3
|
|
19.3
|
|
||||
Southwest
|
8.0
|
|
8.0
|
|
||||
Southeast
|
7.6
|
|
7.5
|
|
||||
International:
|
||||||||
Canada
|
1.1
|
|
1.1
|
|
||||
Total
|
100.0
|
% |
100.0
|
% |
As of December 31, 2023
|
||||||||
Geographic Region
|
Amortized Cost
|
Fair Value
|
||||||
United States:
|
||||||||
West
|
46.5
|
%
|
46.4
|
%
|
||||
Midwest
|
46.0
|
|
46.0
|
|
||||
Northeast
|
7.5
|
|
7.6
|
|
||||
Total
|
100.0
|
% |
100.0
|
% |
As of December 31, 2024
|
||||||||
Industry (1)
|
Amortized Cost
|
Fair Value
|
||||||
Cannabis
|
76.6
|
%
|
76.7
|
%
|
||||
Finance and Insurance
|
11.3
|
|
11.2
|
|
||||
Information
|
5.4
|
|
5.4
|
|
||||
Public Administration
|
3.7
|
|
3.8
|
|
||||
Retail Trade
|
1.2
|
|
1.2
|
|
||||
Health Care and Social Assistance
|
1.0
|
|
1.0
|
|
||||
Real Estate and Rental and Leasing
|
0.8
|
|
0.7
|
|
||||
Total
|
100.0
|
% |
100.0
|
% |
As of December 31, 2023
|
||||||||
Industry (1)
|
Amortized Cost
|
Fair Value
|
||||||
Cannabis
|
100.0
|
%
|
100.0
|
%
|
||||
Total
|
100.0
|
% |
100.0
|
% |
Year Ended
December 31, 2024 |
Year Ended
December 31, 2023 |
|||||||
Beginning Portfolio Investments, at fair value
|
$
|
54,120,000
|
$
|
50,254,550
|
||||
Purchases
|
240,515,638
|
8,442,000
|
||||||
Accretion of discount (amortization of premium), net
|
1,101,295
|
810,554
|
||||||
PIK interest
|
743,775
|
115,725
|
||||||
Proceeds from sales of investments and principal repayments
|
(21,410,831
|
)
|
(6,214,093)
|
|
||||
Net realized gain (loss) on investments
|
(74,483
|
) |
(210,767)
|
|
||||
Net change in unrealized appreciation (depreciation) on investments
|
246,004
|
922,031
|
||||||
Ending Portfolio Investments, at fair value
|
$
|
275,241,398
|
$
|
54,120,000
|
Investment
Performance Risk
Rating
|
Summary Description
|
Grade 1
|
Investments rated 1 involve the least amount of risk to our initial cost basis. The borrower is performing above expectations, and the trends and risk factors for this investment since origination or
acquisition are generally favorable. Full return of principal, interest and dividend income is expected.
|
Grade 2
|
Investment is performing in-line with expectations. Investments rated 2 involve an acceptable level of risk that is similar to the risk at the time of origination or acquisition. Risk factors remain neutral
or favorable compared with initial underwriting. All investments or acquired investments in new portfolio companies are initially assessed a rating of 2.
|
Grade 3
|
Investments rated 3 involve a borrower performing below expectations and indicates that the loan’s risk has increased somewhat since origination or acquisition. Capital impairment or payment delinquency is
not anticipated. The investment may also be out of compliance with certain financial covenants.
|
Grade 4
|
Investments rated 4 involve a borrower performing materially below expectations and indicates that the loan’s risk has increased materially since origination or acquisition. In addition to the borrower being
generally out of compliance with debt covenants, loan payments may be past due (but generally not more than 120 days past due). Delinquency of interest and / or dividend payments in anticipated. No loss of principal is anticipated.
|
Grade 5
|
Investments rated 5 involve a borrower performing substantially below expectations and indicates that the loan’s risk has increased substantially since origination or acquisition. It is anticipated that the
Company will not recoup its initial cost and may realize a loss upon exit. Most or all of the debt covenants are out of compliance and payments are substantially delinquent. Loans rated 5 are not anticipated to be repaid in full and we will
reduce the fair market value of the loan to the amount we anticipate will be recovered.
|
As of December 31, 2024
|
|||||||||
Investment Performance Risk Rating
|
Investments at Fair Value
|
Percentage of Total
Investments
|
|||||||
1
|
$
|
-
|
-
|
%
|
|||||
2
|
275,241,398
|
100.0
|
|
||||||
3
|
-
|
- |
|
||||||
4
|
-
|
- |
|
||||||
5
|
-
|
- |
|
||||||
Total
|
$
|
275,241,398
|
100.0
|
%
|
As of December 31, 2023
|
||||||||
Investment Performance Risk Rating
|
Investments at Fair Value
|
Percentage of Total
Investments
|
||||||
1
|
$
|
-
|
-
|
%
|
||||
2
|
54,120,000
|
100.0
|
%
|
|||||
3
|
-
|
-
|
%
|
|||||
4
|
-
|
-
|
%
|
|||||
5
|
-
|
-
|
%
|
|||||
Total
|
$
|
54,120,000
|
100.0
|
%
|
Year Ended
December 31, 2024 |
Year Ended
December 31, 2023 |
|||||||
Stated interest income
|
$
|
18,060,773
|
$
|
10,810,370
|
||||
Accretion of discount (amortization of premium), net
|
1,101,295
|
810,554
|
||||||
PIK
|
743,775
|
115,725
|
||||||
Total interest income
|
19,905,843
|
11,736,649
|
||||||
Other fee income
|
1,759,910
|
196,251
|
||||||
Total investment income
|
$
|
21,665,753
|
$
|
11,932,900
|
Year Ended
December 31,
2024 |
Year Ended
December 31,
2023
|
$ Change
|
%
Change
|
|||||||||||||
Transaction expenses related to the Loan Portfolio Acquisition
|
5,341,779
|
711,264
|
4,630,515
|
651.0
|
%
|
|||||||||||
Income-based incentive fees
|
2,327,448
|
1,511,253
|
816,195
|
54.0
|
%
|
|||||||||||
Management fee
|
1,504,239
|
1,013,764
|
490,475
|
48.4
|
%
|
|||||||||||
General and administrative expenses
|
700,000
|
-
|
700,000
|
100.0
|
%
|
|||||||||||
Professional fees |
527,358 | 435,090 | 92,268 | 21.2 | % |
|||||||||||
Audit expense
|
497,200
|
499,698
|
(2,498
|
)
|
(0.5
|
%)
|
||||||||||
Administrator fees
|
449,974
|
335,253
|
114,721
|
34.2
|
%
|
|||||||||||
Other expenses |
430,254 | 355,672 | 74,582 | 21.0 | % |
|||||||||||
Legal expenses
|
282,156
|
343,824
|
(61,668
|
)
|
(17.9
|
%)
|
||||||||||
Excise tax expense
|
120,024
|
10,655
|
109,369
|
1026.5
|
%
|
|||||||||||
Capital gains incentive fees
|
34,304
|
87,583
|
(53,279
|
)
|
(60.8
|
%)
|
||||||||||
Total operating expenses
|
12,214,736
|
5,304,056
|
6,910,680
|
130.3
|
%
|
Year Ended
December 31, 2024 |
Year Ended
December 31, 2023 |
|||||||
Total net realized gain (loss)
|
$
|
(74,483
|
)
|
$
|
(210,767
|
)
|
||
Value change from previous year
|
136,284
|
|
(210,767
|
)
|
||||
Percentage change from previous year
|
65
|
%
|
-
|
Year Ended
December 31, 2024 |
Year Ended
December 31, 2023 |
|||||||
Gross unrealized appreciation
|
$
|
956,472
|
$
|
995,334
|
||||
Gross unrealized depreciation
|
(710,468
|
)
|
(73,303
|
)
|
||||
Total net change in unrealized appreciation (depreciation) from investments
|
$
|
246,004
|
$
|
922,031
|
Year Ended
December 31, 2024 |
Year Ended
December 31,
2023
|
|||||||
Aeriz Holdings Corp
|
$
|
(53,418
|
)
|
$
|
-
|
|||
Ascend Wellness Holdings, Inc.
|
(23,395
|
)
|
-
|
|||||
Aura Home, Inc
|
(10,265
|
)
|
-
|
|||||
Curaleaf Holdings, Inc.
|
(40,141
|
)
|
150,678
|
|||||
Deep Roots Harvest, Inc.
|
(25,000
|
)
|
-
|
|||||
Dreamfields Brands, Inc. (d/b/a Jeeter)
|
(4,907
|
)
|
91,226
|
|||||
Elevation Cannabis, LLC
|
263,704
|
-
|
||||||
Flowery - Bill’s Nursery, Inc.
|
61,103
|
-
|
||||||
HA-MD, LLC
|
3,608
|
-
|
||||||
Hartford Gold Group, LLC (Maturity: 12/17/2025)
|
12,063
|
-
|
||||||
Hartford Gold Group, LLC (Maturity: 1/6/2027)
|
23,560
|
-
|
||||||
Minden Holdings, LLC
|
3,176
|
-
|
||||||
Nova Farms, LLC
|
237,595
|
-
|
||||||
Oasis - AZ GOAT AZ LLC
|
(4,033
|
)
|
-
|
|||||
PharmaCann, Inc
|
135,369
|
(73,303
|
)
|
|||||
Proper Holdings, LLC
|
3,130
|
-
|
||||||
Protect Animals With Satellites LLC (Halo Collar): Term Loan
|
(9,643
|
)
|
-
|
|||||
Protect Animals With Satellites LLC (Halo Collar): Incremental Term Loan
|
(6,441
|
)
|
-
|
|||||
Remedy - Maryland Wellness, LLC
|
44,729
|
-
|
||||||
RTCP, LLC
|
19,948
|
-
|
||||||
STIIIZY, Inc. (f/k/a Shryne Group Inc.)
|
(185,946
|
)
|
278,258
|
|||||
Simspace Corporation
|
(72,959
|
)
|
-
|
|||||
Subsero Holdings - Illinois, Inc
|
9,416
|
-
|
||||||
Sunny Days Enterprises, LLC
|
43,094
|
-
|
||||||
Tulip.io Inc.
|
(30,143
|
)
|
-
|
|||||
Verano Holdings Corp.
|
(208,031
|
)
|
475,172
|
|||||
West Creek Financial Holdings, Inc. dba Koalafi
|
(18,320
|
)
|
-
|
|||||
Workbox Holdings, Inc.
|
46,493
|
-
|
||||||
Youth Opportunity Investments, LLC
|
49,484
|
-
|
||||||
Workbox Holdings, Inc: A-3 Warrants
|
(5,785
|
)
|
-
|
|||||
Workbox Holdings, Inc: A-4 Warrants
|
(12,041
|
)
|
-
|
|||||
Total net change in unrealized appreciation (depreciation) from investments
|
$
|
246,004
|
$
|
922,031
|
• |
With respect to investments for which market quotations are readily available, those investments will typically be valued at the bid price of those market quotations;
|
• |
With respect to investments for which market quotations are not readily available, the valuation process begins with the Adviser’s valuation committee establishing a preliminary valuation of each investment, which may be based on
valuations, or ranges of valuations, provided by independent valuation firm(s);
|
• |
Preliminary valuations are documented and discussed by the Adviser’s valuation committee and, where appropriate, the independent valuation firm(s); and
|
• |
The Adviser determines the fair value of each investment.
|
• |
Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;
|
• |
Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active,
or for which all significant inputs are observable, either directly or indirectly; and
|
• |
Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
|
Change in Interest Rates
|
Interest Income
|
Interest Expense
|
Net Income/(Loss)
|
|||||||||
Up 300 basis points
|
$
|
39,514
|
$
|
-
|
$
|
39,514
|
||||||
Up 200 basis points
|
37,308
|
-
|
37,308
|
|||||||||
Up 100 basis points
|
35,102
|
-
|
35,102
|
|||||||||
Down 100 basis points
|
(32,184
|
)
|
-
|
(32,184
|
)
|
|||||||
Down 200 basis points
|
(31,410
|
)
|
-
|
(31,410
|
)
|
|||||||
Down 300 basis points
|
(30,782
|
)
|
-
|
(30,782
|
)
|
Change in Interest Rates
|
Interest Income
|
Interest Expense
|
Net Income/(Loss)
|
|||||||||
Up 300 basis points
|
$
|
6,103
|
$
|
-
|
$
|
6,103
|
||||||
Up 200 basis points
|
3,897
|
-
|
3,897
|
|||||||||
Up 100 basis points
|
1,691
|
-
|
1,691
|
|||||||||
Down 100 basis points
|
(1,227
|
)
|
-
|
(1,227
|
)
|
|||||||
Down 200 basis points
|
(2,001
|
)
|
-
|
(2,001
|
)
|
|||||||
Down 300 basis points
|
(2,629
|
)
|
-
|
(2,629
|
)
|
December 31, 2024
|
December 31, 2023
|
|||||||
ASSETS
|
||||||||
Investments at fair value:
|
||||||||
Non-control/non-affiliate investments at fair value (amortized cost of $
respectively)
|
$
|
|
$
|
|
||||
Cash and cash equivalents
|
|
|
||||||
Receivable for investment sold
|
||||||||
Interest receivable
|
|
|
||||||
s |
||||||||
Prepaid expenses and other assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES
|
||||||||
Transaction fees payable related to the Loan Portfolio Acquisition |
$ | $ | ||||||
Income-based incentive fees payable |
||||||||
Offering costs payable |
||||||||
Due to affiliates |
||||||||
Management fee payable
|
|
|
||||||
Professional fees payable
|
|
|
||||||
Capital gains incentive fees payable |
||||||||
Excise tax payable |
||||||||
Deferred financing costs payable |
||||||||
Other payables |
|
|||||||
Unearned interest income |
||||||||
Distributions payable | ||||||||
Total liabilities
|
$
|
|
$
|
|
||||
Commitments and contingencies (Note 6)
|
||||||||
NET ASSETS
|
||||||||
Common stock, $
|
|
|
||||||
Additional paid-in-capital
|
|
|
||||||
Distributable earnings (accumulated loss)
|
(
|
)
|
|
|||||
Total net assets
|
$
|
|
$
|
|
||||
NET ASSET VALUE PER SHARE
|
$
|
|
$
|
|
For the years ended December 31,
|
For the period
from
April 1, 2022 through
December 31,
2022*
|
|||||||||||
2024 |
2023 |
|||||||||||
INVESTMENT INCOME
|
||||||||||||
Non-control/non-affiliate investment income
|
||||||||||||
Interest income
|
$
|
|
$
|
|
$
|
|
||||||
Fee income
|
|
|
|
|||||||||
Total investment income
|
|
|
|
|||||||||
EXPENSES
|
||||||||||||
Transaction expenses related to the Loan Portfolio Acquisition
|
||||||||||||
Income-based incentive fees
|
||||||||||||
Management fee
|
|
|
|
|||||||||
General and administrative expenses
|
||||||||||||
Professional fees
|
||||||||||||
Audit expense
|
|
|
|
|||||||||
Administrator fees
|
||||||||||||
Other expenses
|
||||||||||||
Legal expenses
|
|
|
|
|||||||||
Excise tax expense
|
||||||||||||
Capital gains incentive fees
|
||||||||||||
Total expenses
|
|
|
|
|||||||||
NET INVESTMENT INCOME (LOSS)
|
|
|
|
|||||||||
NET REALIZED GAIN (LOSS) FROM INVESTMENTS
|
||||||||||||
Non-controlled non-affiliate investments
|
( |
) | ( |
) | ||||||||
Net realized gain (loss) from investments
|
( |
) | ( |
) | ||||||||
NET CHANGE IN UNREALIZED APPRECIATION (DEPRECIATION) FROM INVESTMENTS
|
||||||||||||
Non-controlled/non-affiliate investments
|
|
|
(
|
)
|
||||||||
Net change in unrealized appreciation (depreciation) from investments
|
|
|
(
|
)
|
||||||||
Net realized and unrealized gains (losses) |
( |
) | ||||||||||
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS
|
|
|
|
|
|
|
||||||
NET INVESTMENT INCOME (LOSS) PER SHARE - BASIC AND DILUTED
|
$
|
|
$
|
|
$ | |||||||
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS PER SHARE - BASIC AND DILUTED
|
$
|
|
$
|
|
$ | |||||||
WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC AND DILUTED
|
|
|
* |
On November 8, 2022, our Board of Directors approved a change in our fiscal year end from March 31 to December 31.
|
Common Stock
|
||||||||||||||||||||
|
Shares
|
Par Value
|
Additional
paid-in-
capital
|
Distributable
Earnings/
(Accumulated
Loss)
|
Total
Net Assets
|
|||||||||||||||
Balance, December 31, 2023
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||||
Net increase (decrease) in net assets resulting from operations
|
||||||||||||||||||||
Net investment income (loss)
|
-
|
|
|
|
|
|||||||||||||||
Net realized gain (loss) from investments
|
-
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Net change in unrealized appreciation (depreciation) from
investments
|
-
|
|
|
|
|
|||||||||||||||
Total net increase (decrease) in net assets resulting from operations
|
- |
- |
||||||||||||||||||
Distributions to stockholders from: | ||||||||||||||||||||
Investment income-net
|
- | ( |
) | ( |
) | |||||||||||||||
Capital transactions
|
||||||||||||||||||||
Issuance of common stock, net of offering costs
|
|
|
|
|
|
|||||||||||||||
Reinvestment of stockholder distributions
|
||||||||||||||||||||
Total net increase (decrease) in net assets from capital
transactions
|
||||||||||||||||||||
Total increase (decrease) in net assets
|
|
|
|
(
|
)
|
|
||||||||||||||
Effect of permanent adjustments
|
-
|
|
(
|
)
|
|
|
||||||||||||||
Balance, December 31, 2024
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
Common Stock
|
||||||||||||||||||||
|
Shares
|
Par Value
|
Additional
paid-in-
capital
|
Distributable
Earnings/
(Accumulated
Loss)
|
Total
Net Assets
|
|||||||||||||||
Balance, December 31, 2022
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||||
Net increase (decrease) in net assets resulting from operations
|
||||||||||||||||||||
Net investment income (loss)
|
-
|
|
|
|
|
|||||||||||||||
Net realized gain (loss) from investments
|
-
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Net change in unrealized appreciation (depreciation) from
investments
|
-
|
|
|
|
|
|||||||||||||||
Total net increase (decrease) in net assets resulting from
operations
|
- |
- |
||||||||||||||||||
Distributions to stockholders from: | ||||||||||||||||||||
Investment income-net | - | ( |
) | ( |
) | |||||||||||||||
Capital transactions
|
||||||||||||||||||||
Issuance of common stock, net of offering costs
|
|
|
|
|
|
|||||||||||||||
Reinvestment of stockholder distributions
|
||||||||||||||||||||
Total net increase (decrease) in net assets from capital
transactions
|
||||||||||||||||||||
Total increase (decrease) in net assets
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Effect of permanent adjustments
|
-
|
|
|
(
|
)
|
|
||||||||||||||
Balance, December 31, 2023
|
|
$
|
|
$
|
|
$
|
|
$
|
|
Common Stock
|
||||||||||||||||||||
|
Shares
|
Par Value
|
Additional
paid-in-
capital
|
Distributable
Earnings/
(Accumulated
Loss)
|
Total
Net Assets
|
|||||||||||||||
Balance, March 31, 2022
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||||||
Net increase (decrease) in net assets resulting from operations
|
||||||||||||||||||||
Net investment income (loss)
|
-
|
|
|
|
|
|||||||||||||||
Net realized gain (loss) from investments
|
-
|
|
|
|
|
|||||||||||||||
Net change in unrealized appreciation (depreciation) from investments
|
-
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Total net increase (decrease) in net assets resulting from
operations
|
- |
- |
||||||||||||||||||
Distributions to stockholders from: |
||||||||||||||||||||
Investment income-net
|
- | |||||||||||||||||||
Capital transactions
|
||||||||||||||||||||
Issuance of common stock, net of offering costs
|
|
|
|
|
|
|||||||||||||||
Reinvestment of stockholder distributions
|
||||||||||||||||||||
Total net increase (decrease) in net assets from capital
transactions
|
|
|
|
|
|
|||||||||||||||
Total increase (decrease) in net assets
|
||||||||||||||||||||
Effect of permanent adjustments
|
-
|
|
|
|
|
|||||||||||||||
Balance, December 31, 2022*
|
|
$
|
|
$
|
|
$
|
|
$
|
|
* |
On November 8, 2022, our Board of Directors approved a change in our fiscal year end from March 31 to December 31.
|
For the years ended December 31,
|
For the period
from
April 1, 2022
through
December 31,
2022*
|
|||||||||||
2024 |
2023 |
|||||||||||
Cash flows from operating activities
|
||||||||||||
Net increase (decrease) in net assets resulting from operations
|
$
|
|
$
|
|
$
|
|
||||||
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities:
|
||||||||||||
Net realized (gain) loss from investments
|
||||||||||||
Net change in unrealized (appreciation) depreciation from investments
|
(
|
)
|
(
|
)
|
|
|||||||
Net (accretion of discounts) and amortization of premiums
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Purchase of investments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
PIK interest capitalized
|
( |
) | ( |
) | ||||||||
Proceeds from sales of investments and principal repayments
|
||||||||||||
(Increase) Decrease in operating assets:
|
||||||||||||
Interest receivable
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Receivable for investment sold
|
( |
) | ||||||||||
Due from affiliates
|
( |
) | ||||||||||
Prepaid expenses and other assets
|
(
|
)
|
(
|
)
|
|
|||||||
Increase (Decrease) in operating liabilities:
|
||||||||||||
Income-based incentive fees payable
|
|
|
|
|||||||||
Management fee payable
|
|
|
|
|||||||||
Capital gains incentive fees payable
|
|
|
|
|||||||||
Professional fees payable
|
|
|
|
|||||||||
Transaction fees payable related to the Loan Portfolio Acquisition
|
||||||||||||
Other payables
|
( |
) | ||||||||||
Due to affiliates
|
|
(
|
)
|
(
|
)
|
|||||||
Excise tax payable
|
( |
) | ||||||||||
Deferred income payable
|
||||||||||||
Offering cost payable
|
|
|
(
|
)
|
||||||||
Organizational costs payable
|
|
|
(
|
)
|
||||||||
Net cash (used in) provided by operating activities
|
(
|
)
|
|
(
|
)
|
|||||||
Cash flows from financing activities
|
||||||||||||
Proceeds from issuance of common stock
|
|
|
|
|||||||||
Offering costs paid
|
( |
) | ||||||||||
Distributions paid
|
( |
) | ( |
) | ||||||||
Net cash (used in) provided by financing activities
|
(
|
)
|
(
|
)
|
|
|||||||
Net (decrease) increase in cash and cash equivalents
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Cash and cash equivalents, beginning of period
|
|
|
|
|||||||||
Cash and cash equivalents, end of period
|
$
|
|
$
|
|
$
|
|
||||||
Supplemental disclosure and non-cash financing and investing activity |
||||||||||||
Loans acquired for issuances of shares of common stock
|
$ | $ | $ | |||||||||
Reinvestment of dividend distributions
|
||||||||||||
Accrual for deferred financing costs (Note 2)
|
||||||||||||
Accrual for deferred offering costs (Note 2)
|
||||||||||||
Excise taxes paid
|
* |
On November 8, 2022, our Board of Directors approved a change in our fiscal year end from March 31 to December 31.
|
Portfolio Company
|
Facility Type
|
All-in
Rate
|
Bench-
mark(3)
|
Spread
|
PIK
|
Floor
|
Initial Acquisition Date
|
Maturity
|
Par(2)
|
Amortized
Cost(17)
|
Fair
Value(4)
|
% of Net
Assets |
Tickmark
|
|||||||||||||||||||||||||||||
Investments at Fair Value
|
(1)(5
|
)
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
$
|
|
$
|
|
$
|
|
|
%
|
(9
|
)
|
|||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(11
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(11
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(12
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(12
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
%
|
(11
|
)
|
|||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(11
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(11
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10)(14
|
)
|
||||||||||||||||||||||||
Total Cannabis
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Finance and Insurance
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(11
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(11
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
Total Finance and Insurance
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Health Care and Social Assistance
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
Total Health Care and Social Assistance
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Information
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
Total Information
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Public Administration
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
Total Public Administration
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Real Estate and Rental and Leasing
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
Total Real Estate and Rental and Leasing
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Retail Trade
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
Total Retail Trade
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total First Lien Senior Secured U.S. Debt
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Senior Secured U.S. Notes
|
||||||||||||||||||||||||||||||||||||||||||
Cannabis
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9)(14
|
)
|
||||||||||||||||||||||||
Total Cannabis
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Finance and Insurance
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(13
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(12
|
)
|
||||||||||||||||||||||||
Total Finance and Insurance
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total Senior Secured U.S. Notes
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total U.S. Corporate Debt
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
Information
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(8)(14
|
)
|
||||||||||||||||||||||||
Total Information
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total First Lien Senior Secured Canadian Debt
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total Canadian Corporate Debt
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total Debt Investments
|
|
|
|
%
|
Portfolio Company
|
Class Series
|
Initial
Acquisition Date
|
Shares
|
Amortized
Cost (17)
|
Fair Value
|
% of Net
Assets
|
Tickmark
|
|||||||||||||||
U.S. Preferred Stock
|
||||||||||||||||||||||
Real Estate and Rental and Leasing
|
||||||||||||||||||||||
|
|
|
|
|
|
|
%
|
(6)(10
|
)
|
|||||||||||||
Total Real Estate and Rental and Leasing
|
|
|
|
%
|
||||||||||||||||||
Total U.S. Preferred Stock
|
|
|
|
%
|
||||||||||||||||||
|
||||||||||||||||||||||
U .S. Warrants
|
||||||||||||||||||||||
Real Estate and Rental and Leasing
|
||||||||||||||||||||||
|
|
|
|
|
|
|
%
|
(6)(10
|
)
|
|||||||||||||
|
|
|
|
|
|
|
%
|
(6)(10
|
)
|
|||||||||||||
Total Real Estate and Rental and Leasing
|
|
|
|
%
|
||||||||||||||||||
Total U.S. Warrants
|
|
|
|
%
|
||||||||||||||||||
Canadian Warrants Information
|
||||||||||||||||||||||
|
|
|
|
|
|
|
%
|
(6)(8)(14
|
)
|
|||||||||||||
Total Information
|
|
|
|
%
|
||||||||||||||||||
Total Canadian Warrants
|
|
|
|
%
|
||||||||||||||||||
Total Equity Investments
|
|
|
|
%
|
||||||||||||||||||
TOTAL INVESTMENTS
|
|
|
|
%
|
Portfolio Company
|
Yield
|
Cost
|
Fair Value
|
% of Net Assets
|
Tickmark
|
|||||||||||||||
Cash & Cash Equivalents
|
||||||||||||||||||||
|
|
%
|
|
|
|
%
|
(15)(16
|
)
|
||||||||||||
Total Cash & Cash Equivalents
|
|
|
|
%
|
||||||||||||||||
Total Portfolio Investments and Cash & Cash Equivalents
|
|
|
|
%
|
(1)
|
|
(2)
|
|
(3)
|
|
(4)
|
|
(5)
|
|
(6)
|
|
(7)
|
Geographic regions are determined by the respective portfolio company’s headquarters’ location.
|
(8)
|
|
(9)
|
(10)
|
|
(11)
|
|
(12)
|
|
(13)
|
|
(14)
|
|
(15)
|
|
(16)
|
|
(17)
|
|
Portfolio Company
|
Facility Type
|
All-in
Rate
|
Bench-mark (3)
|
Spread
|
PIK
|
Floor
|
Initial Acquisition Date
|
Maturity
|
Par (2)
|
Amortized
Cost (14)
|
Fair
Value (4)
|
% of Net
Assets
|
Tickmark
|
|||||||||||||||||||||||||||||
Investments at Fair Value
|
(1)(5
|
)
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
$
|
|
$
|
|
$
|
|
|
%
|
(10
|
)
|
|||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(10
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9)(11
|
)
|
||||||||||||||||||||||||
Total Cannabis
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total First Lien Senior Secured U.S. Debt
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(8)(11
|
)
|
||||||||||||||||||||||||
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
|
|
|
|
|
%
|
(9
|
)
|
||||||||||||||||||||||||
Total Cannabis
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total Senior Secured U.S. Notes
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total U.S. Corporate Debt
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total Debt Investments
|
$
|
|
$
|
|
|
%
|
||||||||||||||||||||||||||||||||||||
Portfolio Company
|
Yield
|
Cost
|
Fair
Value
|
% of Net Assets
|
Tickmark
|
|||||||||||||||||||||||||||||||||||||
Cash & Cash Equivalents
|
||||||||||||||||||||||||||||||||||||||||||
|
|
%
|
|
|
|
%
|
(12)(13
|
)
|
||||||||||||||||||||||||||||||||||
Total Cash & Cash Equivalents
|
|
|
|
%
|
||||||||||||||||||||||||||||||||||||||
Total Portfolio Investments and Cash & Cash Equivalents
|
$
|
|
$
|
|
|
%
|
(1)
|
Unless otherwise indicated, all securities are valued using significant unobservable inputs, which are categorized as Level 3 assets under the definition of Financial Accounting
Standards Board’s Accounting Standards Codification 820 Fair Value Hierarchy.
|
(2)
|
Par is net of repayments, if any, as per the terms of the debt instrument’s contract.
|
(3)
|
|
(4)
|
All investments were valued at fair value. See Note 4 — Fair Value of Financial Instruments in the accompanying notes to the financial statements.
|
(5)
|
The Company uses the North American Industry Classification System (“NAICS”) code for classifying the industry grouping of its portfolio companies, excluding any portfolio company
operating in the cannabis industry.
|
(6)
|
Indicates a non-income producing investment. As of December 31, 2023, no investments are deemed as non-income producing. All equity and warrant investments are non-income
producing as of December 31, 2023 unless otherwise noted
|
(7)
|
Geographic regions are determined by the respective portfolio company’s headquarters’ location.
|
(8)
|
Portfolio company located in the Northeast.
|
(9)
|
Portfolio company located in the Midwest.
|
(10)
|
Portfolio company located in the West.
|
(11)
|
|
(12)
|
|
(13)
|
Included within ‘Cash and cash equivalents’ on the Consolidated Statements of Assets and Liabilities.
|
(14)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
•
|
With respect to investments for which market quotations are readily available, those investments will typically be valued at the bid price of those market quotations;
|
•
|
With respect to investments for which market quotations are not readily available, the valuation process begins with the Adviser’s valuation committee establishing a preliminary valuation of each
investment, which may be based on valuations, or ranges of valuations, provided by independent valuation firm(s);
|
•
|
Preliminary valuations are documented and discussed by the Adviser’s valuation committee and, where appropriate, the independent
valuation firm(s); and
|
•
|
The Adviser determines the fair value of each investment.
|
•
|
Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;
|
•
|
Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in
markets that are not active, or for which all significant inputs are observable, either directly or indirectly; and
|
•
|
Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
|
As of December 31, 2024
|
||||||||||||||||||||||||
Investment Type
|
Principal Balance
|
Percentage
at
Principal
Balance
|
Amortized
Cost(1)
|
Percentage
at
Amortized
Cost
|
Fair Value
|
Percentage
at
Fair Value
|
||||||||||||||||||
First Lien Senior Secured Loans
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
Senior Secured Notes
|
|
|
|
|
|
|
||||||||||||||||||
Preferred Stock
|
|
|
|
|
|
|
||||||||||||||||||
Warrants
|
|
|
|
|
|
|
||||||||||||||||||
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
As of December 31, 2023
|
||||||||||||||||||||||||
Investment Type
|
Principal Balance
|
Percentage
at
Principal
Balance
|
Amortized
Cost(1)
|
Percentage
at
Amortized Cost |
Fair Value
|
Percentage
at
Fair Value
|
||||||||||||||||||
First Lien Senior Secured Loans
|
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
Senior Secured Notes
|
|
|
|
|
%
|
|
|
|||||||||||||||||
Total
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
As of December 31, 2024
|
|||||||||||||
Rate Type
|
Principal Balance
|
Amortized Cost(1)
|
Fair Value
|
Time to Maturity
|
|||||||||
Fixed-rate loans
|
$
|
|
$
|
|
$
|
|
|
||||||
Floating-rate loans (SOFR)
|
|
|
|
|
|||||||||
Floating-rate loans (Prime)
|
|
|
|
|
|||||||||
Total Debt Investments
|
$
|
|
$
|
|
$
|
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
As of December 31, 2023
|
|||||||||||||
Rate Type
|
Principal Balance
|
Amortized Cost(1)
|
Fair Value
|
Time to Maturity
|
|||||||||
Fixed-rate loans
|
$
|
|
$
|
|
$
|
|
|
||||||
Floating-rate loans (Prime)
|
|
|
|
|
|||||||||
Total Debt Investments
|
$
|
|
$
|
|
$
|
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
As of December 31, 2024
|
||||||||||||||||
Industry
|
Amortized Cost(1)
|
Percentage at Amortized Cost
|
Fair Value
|
Percentage at
Fair Value
|
||||||||||||
Cannabis
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||
Finance and Insurance
|
|
|
|
|
||||||||||||
Information
|
|
|
|
|
||||||||||||
Public Administration
|
|
|
|
|
||||||||||||
Retail Trade
|
|
|
|
|
||||||||||||
Health Care and Social Assistance
|
|
|
|
|
||||||||||||
Real Estate and Rental and Leasing
|
|
|
|
|
||||||||||||
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
As of December 31, 2023
|
||||||||||||||||
Industry
|
Amortized Cost(1)
|
Percentage at Amortized Cost
|
Fair Value
|
Percentage at
Fair Value
|
||||||||||||
Cannabis
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
As of December 31, 2024
|
||||||||||||||||
Geographic Region
|
Amortized Cost(1)
|
Percentage at Amortized Cost
|
Fair Value
|
Percentage at
Fair Value
|
||||||||||||
United States:
|
||||||||||||||||
Midwest
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||
West
|
|
|
%
|
|
|
%
|
||||||||||
Northeast
|
|
|
%
|
|
|
%
|
||||||||||
Southwest
|
|
|
%
|
|
|
%
|
||||||||||
Southeast
|
|
|
%
|
|
|
%
|
||||||||||
International:
|
||||||||||||||||
Canada
|
|
|
%
|
|
|
%
|
||||||||||
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
As of December 31, 2023
|
||||||||||||||||
Geographic Region
|
Amortized Cost(1)
|
Percentage at Amortized Cost
|
Fair Value
|
Percentage at
Fair Value
|
||||||||||||
United States:
|
||||||||||||||||
West
|
|
|
|
%
|
|
|
%
|
|||||||||
Midwest
|
|
|
%
|
|
|
%
|
||||||||||
Northeast
|
|
|
%
|
|
|
%
|
||||||||||
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
(1)
|
The amortized cost represents the original cost adjusted for any accretion of discounts, amortization of premiums and PIK interest or dividends.
|
•
|
The cannabis industry is extremely speculative and raises a host of legality issues, making it subject to inherent risk;
|
•
|
The manufacture, distribution, sale, or possession of cannabis that is not in compliance with the U.S. Controlled Substances Act is illegal under U.S.
federal law. Strict enforcement of U.S. federal laws regarding cannabis would likely result in our portfolio companies’ inability to execute a business plan in the cannabis industry, and could result in the loss of all or part of
any of our loans;
|
•
|
The current Presidential Administration’s or specifically the U.S. Department of Justice’s change in policies or enforcement with respect to U.S.
federal cannabis laws could negatively impact our portfolio companies’ ability to pursue their prospective business operations and/or generate revenues;
|
•
|
U.S. federal courts may refuse to recognize the enforceability of contracts pertaining to any business operations that are deemed illegal under U.S.
federal law, including cannabis companies operating legally under state law;
|
•
|
Consumer complaints and negative publicity regarding cannabis-related products and services could lead to political pressure on states to implement new
laws and regulations that are adverse to the cannabis industry, to not modify existing, restrictive laws and regulations, or to reverse current favorable laws and regulations relating to cannabis;
|
•
|
Assets collateralizing loans to cannabis businesses may be forfeited to the U.S. federal government in connection with government enforcement actions
under U.S. federal law;
|
•
|
U.S. Food and Drug Administration regulation of cannabis and the possible registration of facilities where cannabis is grown could negatively affect
the cannabis industry, which could directly affect our financial condition and the financial condition of our portfolio companies;
|
•
|
Due to our proposed strategy of investing in portfolio companies engaged in the regulated cannabis industry, our portfolio companies may have a
difficult time obtaining the various insurance policies that are needed to operate such businesses, which may expose us and our portfolio companies to additional risks and financial liabilities;
|
•
|
The cannabis industry may face significant opposition from other industries that perceive cannabis products and services as competitive with their own,
including but not limited to the pharmaceutical industry, adult beverage industry and tobacco industry, all of which have powerful lobbying and financial resources;
|
•
|
Many national and regional banks have been resistant to doing business with cannabis companies because of the uncertainties presented by federal law
and, as a result, we or our portfolio companies may have difficulty borrowing from or otherwise accessing the service of banks, which may inhibit our ability to open bank accounts or otherwise utilize traditional banking services;
|
•
|
Due to our proposed strategy of investing in portfolio companies engaged in the regulated cannabis industry, we or our portfolio companies may have a
difficult time obtaining financing in connection with our investment strategy; and
|
•
|
Laws and regulations affecting the regulated cannabis industry are varied, broad in scope and subject to evolving interpretations, and may restrict the
use of the properties our portfolio companies acquire or require certain additional regulatory approvals, which could materially adversely affect our investments in such portfolio companies.
|
Fair Value Measurements at December 31, 2024 Using
|
||||||||||||||||
Assets
|
Quoted prices in
Active Markets for
Identical Assets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
Significant Other
Unobservable
Inputs (Level 3)
|
Total
|
||||||||||||
First Lien Senior Secured Loans
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Senior Secured Notes
|
|
|
|
|
||||||||||||
Preferred Stock |
||||||||||||||||
Warrants |
||||||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
Fair Value Measurements at December 31, 2023 Using
|
||||||||||||||||
Assets
|
Quoted prices in
Active Markets
for Identical
Assets (Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
Significant Other
Unobservable
Inputs (Level 3)
|
Total
|
||||||||||||
First Lien Senior Secured Loans
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Senior Secured Notes
|
|
|
|
|
||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
Investment Type
|
Fair Value as
of 12/31/2024
|
Valuation
Techniques/Methodologies
|
Unobservable
Input
|
Range
|
Weighted
Average (1)
|
||||||||||
First Lien Senior Secured Loans
|
$
|
|
Discounted Cash Flow
|
Discount Rate
|
|
%
|
|
%
|
|||||||
Senior Secured Notes
|
|
Discounted Cash Flow
|
Discount Rate
|
|
%
|
|
%
|
||||||||
Preferred stock |
Market Approach |
Current Value |
x |
x |
|||||||||||
Warrants |
Option Pricing Model |
Volatility Factor |
% |
% |
|||||||||||
Total
|
$
|
|
(1)
|
|
Investment Type
|
Fair Value as
of 12/31/2023
|
Valuation
Techniques/Methodologies
|
Unobservable
Input
|
Range
|
Weighted
Average (1)
|
||||||||||
First Lien Senior Secured Loans
|
$
|
|
Discounted Cash Flow
|
Discount Rate |
|
%
|
|
%
|
|||||||
Senior Secured Notes
|
|
Discounted Cash Flow
|
Discount Rate |
|
%
|
|
%
|
||||||||
Total
|
$
|
|
(1)
|
The weighted average is calculated based on the fair value of each investment.
|
First Lien Senior
Secured Debt
|
Senior Secured
Notes |
Preferred
Stock
|
Warrants |
Total
|
||||||||||||||||
Balance as of December 31, 2023
|
$
|
|
$
|
|
$ | $ |
$
|
|
||||||||||||
Purchase of investments
|
|
|
|
|||||||||||||||||
Net (accretion of discounts) and amortization of premiums
|
|
|
|
|||||||||||||||||
PIK interest capitalized |
|
|
|
|||||||||||||||||
Proceeds from sales of investments and principal repayments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||
Net realized gain (loss) on investments
|
( |
) | ( |
) | ||||||||||||||||
Net change in unrealized appreciation (depreciation) on investments
|
( |
) | ||||||||||||||||||
Balance as of December 31, 2024
|
$
|
|
$
|
|
$ | $ |
$
|
|
||||||||||||
Net change in appreciation/depreciation on
Level 3 investments still held as of December 31, 2024
|
$
|
|
$
|
|
$ | $ | ( |
) |
$
|
|
First Lien Senior Secured Debt
|
Senior Secured Notes
|
Total
|
||||||||||
Balance as of December 31, 2022
|
$
|
|
$
|
|
$
|
|
||||||
Purchase of investments
|
|
|
|
|||||||||
Net (accretion of discounts) and amortization of premiums
|
|
|
|
|||||||||
PIK interest capitalized
|
|
|
|
|||||||||
Proceeds from sales of investments and principal repayments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net realized gain (loss) on investments
|
( |
) | ( |
) | ||||||||
Net change in unrealized appreciation (depreciation) on investments
|
||||||||||||
Balance as of December 31, 2023
|
$
|
|
$
|
|
$
|
|
||||||
Net change in appreciation/depreciation on
Level 3 investments still held as of December 31, 2023
|
$
|
|
$
|
|
$
|
|
For the years ended December 31,
|
For the period from
April 1, 2022
through
December 31,
2022*
|
|||||||||||
2024
|
2023
|
|||||||||||
Affiliate Payments
|
||||||||||||
Income-based incentive fees
|
$
|
|
$
|
|
$
|
|
||||||
Management fee
|
|
|
|
|||||||||
Capital gains incentive fees
|
|
|
|
|||||||||
Total management and incentive fees earned
|
$
|
|
$
|
|
$
|
|
||||||
General and administrative expenses reimbursable to the Adviser
|
|
|
|
|||||||||
Total
|
$
|
|
$
|
|
$
|
|
* | On November 8, 2022, our Board approved a change in our fiscal year end from March 31 to December 31. |
As of December 31,
|
||||||||
2024
|
2023
|
|||||||
Unfunded delayed draw loan commitments
|
$
|
|
$
|
|
||||
Total undrawn commitments
|
$
|
|
$
|
|
Declaration Date
|
Type
|
Record Date
|
Payment Date
|
Per Share
Amount
|
Dividends
Paid
|
|||||||||
|
|
|
|
$
|
|
$
|
|
|||||||
|
|
|
|
$
|
|
$
|
|
|||||||
|
|
|
|
$
|
|
$
|
|
|||||||
|
|
|
|
$
|
|
$
|
|
|||||||
$ | $ | |||||||||||||
$ | $ | |||||||||||||
$ | $ | |||||||||||||
$ | $ |
Declaration Date
|
Type
|
Record Date
|
Payment Date
|
Shares
|
||||||
|
|
|
|
|
||||||
|
|
|
|
|
||||||
|
|
|
|
|
||||||
|
|
|
|
|
Declaration Date
|
Type
|
Record Date
|
Payment Date
|
Shares
|
||||||
|
|
|
|
|
||||||
|
|
|
|
|
||||||
|
|
|
|
|
||||||
|
|
|
|
|
|
Year Ended
December 31,
2024
|
Year Ended
December 31,
2023
|
For the period
from
April 1, 2022
through
December 31,
2022*
|
|||||||||
Net increase (decrease) in net assets resulting from operations
|
$
|
|
$
|
|
|
$
|
|
|||||
Weighted Average Shares Outstanding - basic and diluted
|
|
|
|
|||||||||
Net increase (decrease) in net assets resulting from operations - basic and diluted
|
$
|
|
$
|
|
$
|
|
* | On November 8, 2022, our Board approved a change in our fiscal year end from March 31 to December 31. |
December 31, 2024 | December 31, 2023 | |||||||
Increase (decrease) in additional paid in capital
|
$ | ( |
) | $ | ||||
Increase (decrease) in distributable earnings (accumulated loss)
|
( |
) |
For the period from April 1,
2024 through December 31, 2024
|
For the tax year from April 1,
2023 through March 31, 2024
|
|||||||
Ordinary income
|
$
|
|
$
|
|
||||
Long-term capital gain |
||||||||
Return of capital |
||||||||
Total Distributions
|
$
|
|
$
|
|
March 31, 2024
|
March 31, 2023 |
|||||||
Undistributed ordinary income | $ | $ | ||||||
Net unrealized appreciation (depreciation) on investments | ||||||||
Capital loss carry forwards |
( |
) | ||||||
Other temporary differences |
(
|
)
|
( |
) | ||||
Total
|
$
|
(
|
)
|
$ |
December 31, 2024 |
December 31, 2023
|
|||||||
Tax cost of investments and cash equivalents
|
$ |
$
|
|
|||||
Unrealized appreciation
|
|
|
||||||
Unrealized depreciation
|
( |
) |
(
|
)
|
||||
Net unrealized appreciation (depreciation) from investments and cash equivalents
|
$ |
$
|
|
For the years ended December 31,
|
For the period
from April 1,
2022 through
December 31, 2022*
|
For the period
from February 3,
2022 through
March 31, 2022
|
||||||||||||||
2024 | 2023
|
|||||||||||||||
Per share data:
|
||||||||||||||||
Net asset value at beginning of period
|
$ |
$
|
|
$
|
|
$
|
|
|||||||||
Net investment income (loss) (1)
|
|
|
(
|
)
|
||||||||||||
Net realized and unrealized gains/(losses) on investments (1)
|
|
(
|
)
|
|
||||||||||||
Net increase/(decrease) in net assets resulting from operations (1)
|
|
|
(
|
)
|
||||||||||||
Offering costs (2)
|
( |
) |
|
|
(
|
)
|
||||||||||
Permanent tax adjustments
|
|
|
(
|
)
|
||||||||||||
Effect of shares issued |
( |
) | ||||||||||||||
Distributions from net investment income (loss) (3)
|
( |
) |
(
|
)
|
|
|
||||||||||
Net asset value at end of period
|
$ |
$
|
|
$
|
|
$
|
|
|||||||||
Net assets at end of period
|
$ |
$
|
|
$
|
|
$
|
|
|||||||||
Shares outstanding at end of period
|
|
|
|
|||||||||||||
Weighted average net assets
|
$ |
$
|
|
$
|
|
$
|
|
|||||||||
Per share market value at end of period
|
$ |
$
|
|
$
|
|
$
|
|
|||||||||
Total return based on market value (4)
|
% |
(
|
%)
|
(
|
%)
|
(
|
%)
|
|||||||||
Total return based on net asset value (4)
|
% |
|
%
|
|
%
|
(
|
%)
|
|||||||||
Ratio/Supplemental data:
|
||||||||||||||||
Ratio of expenses to average net assets(5)
|
% |
|
%
|
|
%
|
|
%
|
|||||||||
Ratio of net investment income (loss) to average net assets(5)
|
% |
|
%
|
|
%
|
(
|
%)
|
|||||||||
Portfolio turnover(5)
|
% |
|
%
|
N/A
|
N/A
|
Item 9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
Item 12.
|
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
Exhibit
Number
|
Description of Exhibit
|
Purchase Agreement by and between Silver Spike Investment Corp. and Chicago Atlantic Loan Portfolio, LLC dated as of February 18, 2024 (1)
|
|
Articles of Amendment and Restatement of the Company (2)
|
|
Articles of Amendment of the Company (3)
|
|
Amended and Restated Bylaws of the Company (4)
|
|
Description of Securities (5)
|
|
Dividend Reinvestment Plan (6)
|
|
Investment Advisory Agreement by and between the Company and Chicago Atlantic BDC Advisers, LLC (7)
|
|
WATC Custody Agreement (8)
|
|
WAB Custody Agreement(9)
|
|
Administration Agreement by and between Registrant and Chicago Atlantic BDC Advisers, LLC (10)
|
|
License Agreement by and between Registrant and Chicago Atlantic BDC Advisers, LLC (11)
|
|
Services Agreement (12)
|
|
Expense Limitation Agreement, dated October 1, 2024, between the Company and Chicago Atlantic BDC Advisers, LLC (13)
|
|
Credit Agreement (14)
|
|
Code of Ethics of the Company*
|
|
Code of Ethics of Chicago Atlantic BDC Advisers, LLC*
|
|
Insider Trading Policies and Procedures of the Company*
|
|
Power of Attorney (included on signature page hereto)
|
|
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
|
|
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
|
|
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
|
|
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
|
*
|
Filed herewith.
|
(1)
|
Incorporated by reference to Exhibit 2.1 of the Company’s current report on Form 8-K filed on February 23, 2024.
|
(2)
|
Incorporated by reference to Exhibit 3.1 of the Company’s annual report on Form 10-K/A, filed on June 30, 2022.
|
(3)
|
Incorporated by reference to Exhibit 3.2 of the Company’s quarterly report on Form 10-Q filed on November 8, 2024.
|
(4)
|
Incorporated by reference to Exhibit 3.2 of the Company’s annual report on Form 10-K/A, filed on June 30, 2022.
|
(5)
|
Incorporated by reference to Exhibit 4.1 of the Company’s annual report on Form 10-K/A, filed on June 30, 2022.
|
(6)
|
Incorporated by reference to Exhibit 10.1 of the Company’s annual report on Form 10-K/A, filed on June 30, 2022.
|
(7)
|
Incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on October 7, 2024.
|
(8)
|
Incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed on February 18, 2025.
|
(9)
|
Incorporated by reference to Exhibit 10.3 of the Company’s current report on Form 8-K filed on February 18, 2025.
|
(10)
|
Incorporated by reference to Exhibit 10.4 of the Company’s annual report on Form 10-K/A, filed on June 30, 2022.
|
(11)
|
Incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed on October 7, 2024.
|
(12)
|
Incorporated by reference to Exhibit 10.6 of the Company’s annual report on Form 10-K/A, filed on June 30, 2022.
|
(13)
|
Incorporated by reference to Exhibit 10.3 of the Company’s current report on Form 8-K filed on October 7, 2024.
|
(14)
|
Incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on February 18, 2025.
|
CHICAGO ATLANTIC BDC, INC.
|
||
Dated: March 31, 2025
|
By:
|
/s/ Peter Sack
|
Peter Sack
|
||
Chief Executive Officer
|
Name
|
Title
|
|
/s/ Scott Gordon
|
Director, Executive Chairman of the
|
|
Scott Gordon
|
Board of Directors, and Co-Chief Investment Officer
|
|
/s/ Vivek Bunty Bohra
|
Director
|
|
Vivek Bunty Bohra
|
||
/s/ Michael W. Chorske
|
Director
|
|
Michael W. Chorske
|
||
/s/ Americo Da Corte
|
Director
|
|
Americo Da Corte
|
||
/s/ John Mazarakis
|
Director
|
|
John Mazarakis
|
||
/s/ Patrick McCauley
|
Director
|
|
Patrick McCauley
|
||
/s/ Supurna VedBrat |
Director
|
|
Supurna VedBrat
|
||
/s/ Tracey Brophy Warson
|
Director
|
|
Tracey Brophy Warson
|
||
/s/ Peter Sack |
Chief Executive Officer | |
Peter Sack |
(Principal Executive Officer) | |
/s/ Martin Rodgers |
Chief Financial Officer
(Principal Financial and Accounting Officer),
|
|
Martin Rodgers |